

A clinical trial to study the effects of Ayurvedic formulation Suved and Reimmugen (whole cow colostrum) in patients with atherosclerosis

Submission date 28/09/2016	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 07/11/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 27/07/2020	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Atherosclerosis is a condition where the arteries become clogged with fatty substances, increasing the risk of blood clots that can block the flow of blood to the heart or brain. This can lead to life-threatening problems such as heart attacks, strokes and deep vein thrombosis (DVT). Ayurveda is a traditional system of medicine that has been practiced in the Indian subcontinent for over 3000 years. It is based on the belief that health and wellness depend on a delicate balance between the mind, body, and spirit. The aim of this study is to assess the effects of the Ayurvedic formulation Suved and Reimmugen (cow colostrum, a form of milk) in patients with atherosclerosis.

Who can participate?

Patients aged 18 or over with atherosclerosis

What does the study involve?

Participants are randomly allocated to one of two groups. Participants in one group take Suved and Reimmugen. Participants in the other group take a placebo (dummy drug). Participants take these medicines by mouth as capsules for a period of 3 months in addition to their ongoing medication to study the additional benefit to them. All participants undergo tests before treatment and after 3 months of treatment which include ultrasound scans of the heart, carotid artery and lower limbs, and blood tests. Participants' ongoing regular treatment is not changed.

What are the possible benefits and risks of participating?

Possible benefits include relief from symptoms associated with blood clots and cardiac (heart) weakness. The medicines have been used for over 7 years, no side effects have been recorded, and they can be taken with conventional medicines.

Where is the study run from?

Smt. Kashibai Navale Medical College (India)

When is the study starting and how long is it expected to run for?
September 2016 to September 2018

Who is funding the study?
Health Solutions (India)

Who is the main contact?
Dr Sujata Vaidya
drsujatavaidya@gmail.com

Contact information

Type(s)
Scientific

Contact name
Dr Sujata Vaidya

ORCID ID
<https://orcid.org/0000-0003-4965-493X>

Contact details
B 902
Teerth Towers
Baner Annex
Pune
India
411021
+91 (0)982 231 1565
drsujatavaidya@gmail.com

Additional identifiers

ClinicalTrials.gov (NCT)
NCT02920125

Protocol serial number
SKNMC - HS/SHARP/2016, CTRI/2018/02/011848

Study information

Scientific Title
A study to evaluate the results of integrative treatment (Ayurvedic capsules Suved and Reimmugen) for vascular disease

Acronym
SHARP

Study objectives

An equivalence trial in a pragmatic study of the clinical advantages and outcome on addition of Ayurvedic herbal formulation SAVED and cow colostrum Reimmugen to patients with vascular disease complications like ischemic heart disease (IHD), coronary artery disease (CAD), cardiovascular disease (CVD), deep vein thrombosis (DVT), and peripheral arterial disease (PAD). These advantages are clinical (intima-media thickness (IMT) studies) and functional in changes of symptoms associated with atherosclerosis/vascular blockages.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics committee of Smt. Kashibai Navale Medical College and General Hospital, 05/10/2016, ref: SKNMC/Ethical/App/2015/115

Study design

Interventional double-blind placebo-controlled single-centre trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Vascular disease, atherosclerosis

Interventions

Patients are randomised to one of two groups:

1. Suved (Ayurvedic formulation, FDA India approved) and whole cow colostrum Reimmugen. Dosage decided by regular Ayurvedic use Suved 500mg one capsule twice daily: Reimmugen 300 mg one capsule three times daily in chronic subjects. Dose increased to Suved one capsule three times daily and Reimmugen two capsules three times daily in chronic acute subjects.
2. Placebo (everyday grain flour in same packaging to mask content)

These will be given for a period of 3 months in addition to ongoing medication to study the additional benefit to patients in their functional and clinical investigations.

Investigations done pre treatment and after 3 months treatment include the following: electrocardiogram (ECG), 2D echo cardiogram, carotid Doppler, and lower limb Doppler where necessary, angiography in few cases who opt to take the investigations, not compulsory, regular complete blood count (CBC), lipid profile, liver function test (LFT), renal function test (RFT).

Intervention Type

Drug

Phase

Phase III/IV

Drug/device/biological/vaccine name(s)

Suved, Reimmugen

Primary outcome(s)

Restoration of carotid IMT to a non-pathological state, supported with positive changes in functionality and relief from associated symptoms:

1. Clinical investigations will be compared pre - post treatment to evaluate percent changes in IMT and cardiac function as a mark of reversal of atherosclerosis and relief from symptoms associated with blockages in blood vessels due to atherosclerosis. IMT measurements are taken as standard to evaluate atherosclerosis and 2D echo taken for cardiac perfusion.
 2. Functional changes considered on the basis of symptoms of chest pain, breathlessness, stamina of walking or performing daily chores.
- Measured at baseline and at the end of 3 months of treatment.

Key secondary outcome(s)

Development of ischaemic events in other circulations (e.g., in a stroke patient, evaluation of coronaries), assessed at baseline and at the end of 3 months of treatment.

Completion date

01/09/2018

Eligibility**Key inclusion criteria**

Males or females aged 18 or over with a diagnosis of vascular disease leading to IHD, CAD, CVD, DVT or PAD at any stage

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Pregnant and lactating women
2. Patients below age of 18
3. Acute IPD operative condition
4. Patients undergoing interventional procedures/surgical treatments other than for vascular disease, until they are discharged from intensive care
5. Haemorrhagic cerebrovascular stroke

Date of first enrolment

09/10/2016

Date of final enrolment

01/09/2018

Locations

Countries of recruitment

India

Study participating centre

Smt. Kashibai Navale Medical College

Navle

Pune

India

411041

Sponsor information

Organisation

Health Solutions

Organisation

Smt. Kashibai Navale Medical College

Funder(s)

Funder type

Industry

Funder Name

Health Solutions (India)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes